JUL 21, 2020 11:42 AM PDT

Investigating New Anti-Blood Clotting Treatments

WRITTEN BY: Jasper Cantrell

When it comes to your cardiovascular health, it is important to look at more than just your heart. The cardiovascular system could be summarized as a pathway for your blood to run through your body. Any issues with the proper flow of blood can cause major damage to the body. These issues can be things such as heart dysfunction, obstruction of a blood vessel, or (the scariest, in my opinion) blood clots.

Blood clots form when there is an injury to the blood vessels. The body responds by combining platelets with fibrin at the wound, where they coagulate and prevent blood loss. However, abnormal blood clots can block blood flow and cause tissue damage. 

Several things can be done to prevent blood clots, from exercising to a healthy diet, but some factors are out of your control. Scientists have sought to identify any biomarkers against the risk of blood clots and have found a few with promise.

The Von Willebrand factor (VWF) is one such biomarker.  It is a small protein involved in the initial blood clot formation caused by high shearing forces. These shearing forces are usually due to high blood flow surrounding clogged arteries. It is already considered a poor prognostic indicator for cardiovascular health, and anti-VWF drugs have some promise for blood clot treatment and prevention. 

A team from the Medical University of Vienna in Austria sought to test a new anti-VWF drug, BT200. They set up blood clotting experiments using endotoxin (the toxic part of bacteria) and desmopressin (a kidney drug) to activate VWF. They would then treat the blood with BT200 and observe how it affected VWF activity.

BT200 treatment managed to inhibit VWF activation in all cases. The most significant find was that effective BT200 dosage was tied to VWF levels. This gives critical dosage information for future studies, and retroactive analysis showed that this characteristic was shared amongst all VWF inhibitors. Conventional clotting inhibitors usually do not catch VWF dependent clotting, so more research is needed into this treatment pathway.

The team concludes, “Even under conditions of stimulated VWF release, BT200 potently inhibits VWF activity and VWF-dependent platelet function. This is in contrast to conventional platelet inhibitors whose effects are compromised by elevated VWF under high shear rates.”

Sources: Nature Scientific Reports, LearnBlood

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 08, 2021
Cardiology
Strong Links Between PTSD and Heart Disease
AUG 08, 2021
Strong Links Between PTSD and Heart Disease
The link between heart disease and stress is well known, but researchers still have a lot to learn about that associatio ...
SEP 16, 2021
Clinical & Molecular DX
Your T-Shirt Could Soon Tell You if Your Heart Is Ok
SEP 16, 2021
Your T-Shirt Could Soon Tell You if Your Heart Is Ok
Forget uncomfortable chest straps or clunky wristbands—thanks to a new innovation in nanotechnology, your t-shirt ...
SEP 14, 2021
Health & Medicine
A lower sodium diet decreases the chance of stroke and other heart disease
SEP 14, 2021
A lower sodium diet decreases the chance of stroke and other heart disease
A new study found that using a low salt alternative lowered the risk of stroke and other heart disease
SEP 21, 2021
Health & Medicine
The (Not So) Secret To A Happy Life: Fruits, Vegetables, and Exercise
SEP 21, 2021
The (Not So) Secret To A Happy Life: Fruits, Vegetables, and Exercise
Researchers uncover causal link between a healthy lifestyle and satisfaction with life.
SEP 28, 2021
Drug Discovery & Development
The FDA approves drug to treat a bad cholesterol in children
SEP 28, 2021
The FDA approves drug to treat a bad cholesterol in children
Familial hypercholesterolemia (FH) is a genetic disorder that afflicts approximately 1 in 250 people. Interestingly, whi ...
OCT 07, 2021
Health & Medicine
A School-based Approach to Combatting Adolescent Obesity
OCT 07, 2021
A School-based Approach to Combatting Adolescent Obesity
It should come as no surprise that obesity is a significant public health concern associated with astronomical economic ...
Loading Comments...